Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
      • Scientific Advisory Board
    • Facilities
  • Therapeutic Areas
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Long COVID
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-102 SL
      • TNX-1850
      • TNX-801
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling participants in a Phase 3 trial for fibromyalgia, the RESILIENT study. For more information, please visit www.resilientstudy.com or www.clinicaltrials.gov (NCT05273749).

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Tonix in the News
  • Press Releases
  • IR Events
  • Email Alerts
  • Op-Eds
Nov 25, 2014 8:40am EST

Tonix Pharmaceuticals to Present at the LD Micro Investor Conference

Nov 10, 2014 8:40am EST

Tonix Pharmaceuticals Reports Third Quarter 2014 Financial Results

Oct 21, 2014 8:40am EDT

Tonix Pharmaceuticals Receives IND Clearance for TNX-201 in Episodic Tension-Type Headache

Sep 29, 2014 6:00am EDT

Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia

Sep 19, 2014 8:40am EDT

Tonix Pharmaceuticals to Present at the BioCentury NewsMakers Conference

Sep 3, 2014 8:40am EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference

Aug 11, 2014 8:40am EDT

Tonix Pharmaceuticals Announces Transfer to the NASDAQ Global Market

Aug 8, 2014 4:05pm EDT

Tonix Pharmaceuticals Reports Second Quarter 2014 Financial Results

Aug 6, 2014 8:40am EDT

Tonix Pharmaceuticals to Present at Two Investor Conferences in August

Jul 11, 2014 8:20am EDT

Tonix Pharmaceuticals Announces Registered Direct Offering of $7.8 Million

  • Page 1
  • Page 2
  • Page 3
  • Next Pagearrow_forward
rss_feed News RSS
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2022 Tonix Pharmaceuticals Holding Corp.